目的 分析医院铜绿假单胞菌的临床分布及其耐药性,加强重点区域的防控,为临床合理用药提供依据。方法 回顾性分析医院2018-01至2018-12住院患者临床标本中分离出铜绿假单胞菌的来源及分布特征,统计分析药敏试验结果。结果 共检出160株铜绿假单胞菌,从痰标本中分离得到的铜绿假单胞菌最多,为131株(占81.88%)。检出率排名前三位的为神外科53株、ICU48株、呼吸科13株。药敏结果显示,对多黏菌素B最敏感,敏感率为95.0%;对替卡西林/克拉维酸的耐药率最高,为51.2%。结论 铜绿假单胞菌对多黏菌素B、头孢哌酮/舒巴坦、阿米卡星较敏感,应加强对铜绿假单胞菌的耐药性监测,强化临床用药的合理性,针对耐药机制寻找新的抗菌途径。
Abstract
Objective To investigate the clinical distribution and drug resistance of Pseudomonas aeruginosa in order to provide evidence and reference for clinical prevention and treatment.Methods Strains of Pseudomonas aeruginosa were isolated and tested for sensitivity in 2018.Results A total of 160 clinical isolates were collected. The main source of the samples was sputum, which accounted for 81.88%. Pseudomonas aeruginosa infections mainly occurred in the Department of Neurosurgery (53 strains), ICU (48 strains) and Department of Respiratory Disease (13 strains). The 160 strains of pseudomonas aeruginosa were mostly susceptible to polymyxin B (susceptible rate 95.0%), but resistant to ticarcillin/clavulanic acid (resistance rate 51.2%).Conclusions Pseudomonas aeruginosa is susceptible to polymyxin B, cefoperazone/sulbactam and amikacin. Drug resistance of Pseudomonas aeruginosa should be monitored in order to select the right antibiotics in clinic.
关键词
铜绿假单胞菌 /
临床分布 /
耐药性 /
碳青霉稀类 /
多黏菌素B
Key words
Pseudomonas aeruginosa /
clinical distribution /
drug resistance /
carbapenem /
polymyxin B
{{custom_sec.title}}
{{custom_sec.title}}
{{custom_sec.content}}
参考文献
[1] 中华医学会呼吸病学分会感染学组. 铜绿假单胞菌下呼吸道感染诊治专家共识[J].中华结核和呼吸杂志, 2014,37(1):9-15.
[2] 王延茹, 张智琪, 高雅婷,等. 喹诺酮信号分子和环丙沙星诱导铜绿假单胞菌对环丙沙星最低抑菌浓度影响的比较[J].中国临床药理学杂志, 2018,34(9):1115-1118.
[3] 李 蓓,骆文玲,解晓悦,等. 2012-2016年本医院内获得性肺炎病原菌分布及革兰阴性杆菌耐药性分析[J].武警医学,2017,28(11):1151-1154.
[4] Goncalves C F, Silva A R, Burth P, et al. Possible mechanisms of pseudomonas aeruginosa -associated lung disease [J].Int J Med Microbiol, 2016,306(1)20-28.
[5] 李绪定. 碳青霉稀类治疗铜绿假单胞菌肺炎的临床效果分析[J].医学信息, 2018,31(13):134-136.
[6] Buhl M, Peter S, Willmann M. Prevalence and risk factors associated with colonization and infection of extensively drug resistant Pseudomonas aeruginosa: a systematic review [J].Expert Rev Anti Infect Ther, 2015, 13(9):1159-1170.
[7] Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing standards[S]. M100-S23, CLSI, 2015.
[8] 胡付品, 郭 燕, 朱德妹, 等. 2017 年CHINET中国细菌耐药性监测[J].中国感染与化疗杂志,2018,18(3):241-251.
[9] 周燕飞, 庞 艳, 王 斌. 铜绿假单胞菌感染临床分布及耐药性分析[J].中华医院感染学杂志,2014,24(17):4177 -4178.
[10] 黄 勋, 邓子德, 倪语星, 等. 多重耐药细菌医院感染预防与控制中国专家共识 [J].中国感染控制杂志,2015, 14(1):1-9.
[11] Magiorakos A P, Srinivasan A, Carey R B, et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance[J]. Clin Microbiol Infect, 2012,18(3):268-281.
[12] 蒋 逸, 沈佳丽, 蒋文玥, 等.34株耐亚胺培南铜绿假单胞菌的药物敏感分析及耐药机制探讨[J].智慧健康,2018, 4(19):19-20.
[13] Nakajima A, Sugimoto Y, Yoneyama H, et al. High-level fluoroquilone resistance in Pseudomonas aeruginosa due to interplay of the MexAB-OprM efflux pump and the DNA gyrase mutation[J]. Med Microbiol Immuno,2002,46(6): 391-395.
[14] 袁瑾懿, 余 慧, 郭 燕, 等.广泛耐药铜绿假单胞菌甲基化酶基因的检测和基因周边结构分析[J].中国感染与化疗杂志,2018,18(3):273-277
[15] 王 芊, 华 川.铜绿假单胞菌对碳青霉烯类抗菌药物耐药现状研究进展[J].解放军医学杂志,2013,25(7):87-89.
[16] Falagas M E, Rafailidis P I, Matthaiou D K. Resistance to polymyxins: mechanisms, frequency and treatment options [J]. Drug Resist Updat, 2013, 13(4-5)132-138.
PDF(591 KB)
